Methods: An open-label, randomized, non-inferiority study was conducted at 57 institutions in Japan. Eligible patients were those who underwent open total gastrectomy for gastric cancer. Patients were assigned randomly to continued use of -lactamase inhibitor for either 24 or 72 h after surgery. The primary endpoint was the incidence of SSI, with non-inferiority based on a margin of 9 percentage points and a 90 per cent c.i. The secondary endpoint was the incidence of remote infection.
Introduction
Surgical resection is the mainstay of curative treatment for gastric cancer. Total gastrectomy is one of the most invasive gastrointestinal procedures and carries substantial surgical risks. Several studies 1 -3 have reported an increased complication rate after total gastrectomy in comparison with subtotal gastrectomy. Moreover, the incidence of surgical-site infection (SSI) after total gastrectomy is reported to be higher than that after distal gastrectomy 4, 5 .
Antimicrobial prophylaxis is used to prevent postoperative SSI for clean-contaminated and some clean surgical procedures. Minimizing the duration of prophylaxis has some benefits, such as suppressing the development of bacterial resistance, reducing the incidence of antibiotic-related complications, and lowering costs. Although some guidelines 6, 7 recommended discontinuation of prophylaxis within 24 h after surgery, most previous studies have focused on either biliary or colorectal surgery. Only three prospective, randomized controlled studies 8 -10 have primarily examined the optimal duration of antibiotic prophylaxis after gastric cancer surgery, all of which demonstrated a lack of efficacy for postoperative antibiotics.
This multicentre randomized study investigated the efficacy of short-term antibiotic prophylaxis after total gastrectomy in Japanese patients. 
Methods
This prospective, randomized, open-label, non-inferiority study was conducted from March 2008 to March 2012. The study protocol (Appendix S1, supporting information) was approved by the Randomized Controlled Trial Committee of the Japanese Society of Surgical Infection and the ethics committees of each institutional review board. The study was conducted in accordance with the Ethical Guidelines for Clinical Studies and the Declaration of Helsinki. All patients provided written informed consent before randomization, and there were no important changes to the methods after the study commenced. This study was registered with the University Hospital Medical Information Network (UMIN)-CTR (http://www.umin.ac.jp), identification number UMIN000001062.
The study took place at 57 institutions in Japan. Patients aged 20-80 years, who were scheduled to undergo elective open, potentially curable total gastrectomy for cancer with D1 or D2 lymphadenectomy 11 , and with an ASA fitness grade of I or II, were included. Potentially curable gastric cancer in this study was defined as macroscopically cured after surgery; patients with macroscopic residual tumour were excluded. The exclusion criteria were: emergency or laparoscopic surgery; bacterial infection at the time of surgery or use of antimicrobial therapy up to 2 weeks before surgery; liver dysfunction (alanine aminotransferase, aspartate aminotransferase or total bilirubin level equal to or more than twice the upper limit of normal); renal insufficiency (blood urea nitrogen level of at least 25 mg/dl or serum creatinine level 1⋅5 mg/dl or more); heart impairment (New York Heart Association functional classification of at least II); preoperative chemotherapy or chemoradiotherapy; and pregnancy or lactation. Although patients undergoing total gastrectomy combined with splenectomy and/or cholecystectomy were included, those undergoing pancreaticosplenectomy or resection of other organs were excluded.
Randomization and masking
Permuted-block randomization through a central computer system was used to assign patients in a 1 : 1 ratio to receive antibiotic prophylaxis for either 24 or 72 h after surgery. The randomization list was prepared centrally by a data management centre (BELSYSTEM24, Tokyo, Japan) using a validated computer program. All eligible patients were randomized at the end of surgery. Randomization was stratified by the preoperative T category (T1, or at least T2).
Procedures
In both groups, the β-lactamase inhibitor ampicillinsulbactam (1⋅5 g) was administered parenterally after induction of anaesthesia, and an additional dose was given if the duration of surgery extended beyond 3 h. For 24 h prophylaxis, postoperative dosing was administered 6 and 18 h after the end of surgery. For 72 h prophylaxis, postoperative dosing was given at 6 h, then twice daily for 72 h. Perioperative care protocols and wound management were as recommended in the guideline developed by the Centers for Disease Control and Prevention (CDC) 6 in both groups. Infection control personnel monitored and detected SSIs during the patients' hospital stay. The principal surgeons were required to check for the presence or absence of SSIs at outpatient clinics until 30 days after operation. The distribution of pathological stage was determined according to the TNM classification system 12 . An independent data and safety monitoring committee reviewed study data approximately every 6 months throughout the study, and no interim analysis of efficacy was performed.
Outcomes
The primary endpoint was the incidence of SSI. Determination of the presence of SSI was based on criteria developed by the CDC 6 . The secondary endpoint was the rate of remote infection, defined as a postoperative infection at a site other than the surgical site, such as pneumonia, enteritis, urinary tract infection or bloodstream (catheter-related) infection during the hospital admission 13 .
Statistical analysis
This study was designed to test the hypothesis that 24 h prophylaxis would not be inferior to 72 h prophylaxis for development of SSIs 30 days after elective open total gastrectomy. The rates of SSI from previous reports vary according to the extent of gastrectomy, ranging between 12 and 19 per cent after total gastrectomy 8, 14, 15 . Therefore, the SSI rate in the 72-h prophylaxis group was anticipated to be 16 per cent, and a 9 per cent non-inferiority margin was used for sample size calculations.
With a 90 per cent c.i. at a one-sided α level of 0⋅05 using the Dunnett-Gent test, a sample size of 412 patients would provide a power of 80 per cent to establish whether 24 h prophylaxis was not inferior to 72 h prophylaxis with regard to the incidence of SSI. Allowing for an ineligibility rate of 10 per cent, the required sample size in this study was 460 patients.
The full analysis set included all randomized participants who received at least one dose of antibiotic prophylaxis and were assessed for the primary endpoint, secondary endpoint and exploratory analyses. The per-protocol population, as defined in the statistical analysis plan, included all randomized patients who completed the study with none of the following prespecified major protocol deviations: did not meet eligibility criteria unless waiver was obtained before enrolment; received treatment different from that to which they were randomized; and did not receive antibiotic prophylaxis before skin incision.
For the secondary endpoint and difference in the distribution of the baseline characteristics between groups, binary variables were analysed using Fisher's exact test, and continuous variables with Student's t test.
Logistic regression analyses for primary and secondary endpoints were performed to adjust for potential confounding factors, including age, sex, BMI, extent of lymphadenectomy, cholecystectomy, splenectomy, duration of operation, pathological tumour category and blood transfusion. Nine subgroups for primary endpoint were also analysed using logistic regression to assess the statistical interaction between the duration of antibiotic prophylaxis and the various groups. Although some subgroups were determined according to postoperative information, it was considered that these factors could be treated similarly to the baseline factors.
The primary endpoint was evaluated with a one-sided α of 0⋅05 and a 90 per cent c.i. Two-sided P values of less Values in parentheses are percentages unless indicated otherwise; *values in parentheses are 90 per cent confidence intervals. †P <0⋅001 (1-sided P value for non-inferiority test); ‡two-sided P value for superiority test. than 0⋅050 were calculated for all other tests. P < 0⋅050 was judged to be statistically significant. Statistical analyses were conducted using SAS ® version 9.1 (SAS Institute, Tokyo, Japan).
Results
A total of 563 participants were assessed and 471 were randomized into two treatment groups (Fig. 1) . Seven patients had data missing, leaving 228 in the 24-h prophylaxis group and 236 in the 72-h prophylaxis group for the primary analysis. Patients' characteristics were balanced between the two groups ( Table 1) . Patients with a tumour category of T2 or greater accounted for 73⋅2 per cent of the 24-h prophylaxis and 76⋅7 per cent of the 72-h prophylaxis groups, and those who had a splenectomy accounted for 33⋅8 and 42⋅0 per cent respectively. Approximately 80 per cent of patients in both groups underwent D2 lymphadenectomy. The overall incidence of SSI was 9⋅9 per cent (46 of 464 patients). The incidence of SSI was 8⋅8 per cent in the 24-h prophylaxis and 11⋅0 per cent in 72-h prophylaxis group (absolute difference −2⋅2 (90 per cent c.i. −6⋅8 to 2⋅4) per cent). This confirmed the non-inferiority of 24 h prophylaxis (P for non-inferiority < 0⋅001). (Table 2 ). There were 47 SSI events in total; one patient in the 72-h prophylaxis group had infection that involved both the superficial incision and organ/space sites. There were no significant differences in the incidence of superficial or deep incisional SSI or organ/space SSI between the two groups. No SSI was recorded in one patient (allocated to 72 h prophylaxis) who had a protocol violation. Analysis of the per-protocol population revealed results similar to those for the full-set population (absolute difference −2⋅3 (90 per cent c.i. −6⋅9 to 2⋅4) per cent; P for non-inferiority < 0⋅001).
On the basis of logistic regression analysis, the unadjusted odds ratio for SSI after 24 h prophylaxis was 0⋅78 (95 per cent c.i. 0⋅42 to 1⋅44) ( Table 3 ). The adjusted odds ratio was 0⋅82 (0⋅43 to 1⋅54) after accounting for nine variables (age, sex, BMI, extent of lymphadenectomy, cholecystectomy, splenectomy, duration of operation, blood transfusion and pathological disease stage) ( Table 3 ). The statistical interactions between duration of antibiotic prophylaxis and patient characteristics were also assessed (Fig. S1, supporting information) . No subgroup showed a decrease in the incidence of SSI with 72 h prophylaxis. The subgroup with pathological disease stages I and II showed a significant benefit with 24 h prophylaxis: odds ratio 0⋅33 (0⋅12 to 0⋅86).
At least one organism was isolated from the surgical sites of 20 patients in the 24-h prophylaxis group (23 organisms) and 26 patients in 72-h group (28 organisms) ( Table S1 , supporting information). The distribution and prevalence of the isolated species were similar between the two groups. 
Values in parentheses are percentages unless indicated otherwise; *values in parentheses are 95 per cent confidence intervals. †Two-sided P value for superiority test.
The incidence of remote infection was 10⋅5 per cent after 24 h prophylaxis and 4⋅7 per cent after 72 h prophylaxis ( Table 4 ). The rate of pulmonary infection was significantly higher after 24 h prophylaxis (6⋅6 versus 2⋅5 per cent). In logistic regression analysis, the unadjusted odds ratio for remote infection after 24 h prophylaxis was 2⋅41 (95 per cent c.i. 1⋅15 to 5⋅04) ( Table S2 , supporting information). The adjusted odds ratio with 24 h prophylaxis was 2⋅73 (1⋅30 to 6⋅06) after accounting for nine variables (age, sex, BMI, extent of lymphadenectomy, cholecystectomy, splenectomy, duration of operation, blood transfusion and pathological disease stage).
Discussion
This non-inferiority study was designed to compare the incidence of SSI in patients given antibiotic prophylaxis for 24 h after elective open total gastrectomy with that in patients given prophylaxis for 72 h after surgery. It concluded that antibiotic prophylaxis for 24 h was as effective, in both the intention-to-treat and per-protocol analyses.
Antibiotic prophylaxis should be administered for the shortest effective interval to minimize adverse effects and costs. Although many guidelines recommend a single dose of antibiotic prophylaxis or its continuation for up to 24 h after surgery 6, 7 , differences still remain in clinical practice 16 -18 . A survey 18 done in South Korea and Japan showed that most institutions preferred to use prophylaxis for longer than 24 h after open gastrectomy. However, long-term postoperative antibiotic prophylaxis led to outbreaks of postoperative methicillin-resistant Staphylococcus aureus infection 19 . Establishing solid evidence in relation to this worldwide issue is therefore worthwhile.
Three large RCTs have examined the optimal duration of antibiotic prophylaxis after gastric cancer surgery, including large numbers of patients who had extended lymphadenectomy. One study 8 randomized 501 patients with gastric cancer, including various types of surgery, such as total gastrectomy, distal gastrectomy and proximal gastrectomy; 282 patients underwent D2 resection.
The incidence of SSI following surgery was similar in both groups (single dose, 9⋅5 per cent; multiple doses, 8⋅6 per cent). The second study 10 randomized 325 patients, and reported that the incidence of SSI following elective gastric cancer surgery was 9⋅1 per cent among patients receiving single-dose cefazolin and 6⋅2 per cent in those receiving an additional five doses every 12 h after operation. The third study 9 analysed a more homogeneous group of patients, all of whom underwent distal gastrectomy. The authors found that single-dose prophylaxis with cefazolin was as effective as additional doses of cefazolin until postoperative day 2 (SSI incidence 5 per cent with single dose versus 9 per cent when multiple dose was used) 9 . However, no study has evaluated the optimal duration of antibiotic prophylaxis with a focus on total gastrectomy, which is one of the most invasive gastrointestinal procedures and has a higher incidence of SSI than distal gastrectomy. Recent data from the Japanese Nosocomial Infections Surveillance 20 suggested that the incidence of SSI after total gastrectomy was 13⋅8 per cent, compared with 7⋅2 per cent after distal gastrectomy.
Several factors, such as ageing, obesity, malnutrition, prolonged operation and combined adjacent organ resection, increase the incidence of SSI 15,21 -23 . In this study, there was no benefit from 72 h prophylaxis in any of nine subgroups. In agreement with Imamura and colleagues 9 , it can be concluded that the optimal duration of antibiotic prophylaxis after gastrectomy for gastric cancer is up to 24 h, regardless of the extent of gastrectomy.
The rate of remote infection after 24 h antibiotic prophylaxis was significantly higher than that after 72 h. Pulmonary infection was mostly responsible for this difference (6⋅6 per cent with 24 h versus 2⋅5 per cent with 72 h prophylaxis). There were no differences in the rates of remote infection in two previously published RCTs 8, 9 . A potential explanation for the present finding was that remote infection is not caused during surgery, but occurs after surgery, and is not related directly to operation. The risk factors for SSI and remote infection may differ 24, 25 . Although the purpose of antibiotic prophylaxis is to prevent SSI, surgeons should note that shortened antimicrobial prophylaxis might increase the risk of remote infection. Other measures, including perioperative respiratory rehabilitation and early mobilization, are effective alternatives in preventing remote infection such as pneumonia 26 .
The present study has several limitations. This was an open study and the assigned group was not blinded. However, the definition of SSI is well established, and assessment of SSI was usually carried out by medical staff members who were not involved in the study. Another limitation is that patients at higher risk of infection, such as those undergoing complex surgery or with chronic renal disease, heart failure, severe diabetes mellitus and similar conditions, were excluded. Therefore, these results cannot be extended to high-risk patients.
The present results confirm that antibiotic prophylaxis for 24 h is adequate for preventing SSI in patients undergoing total gastrectomy with lymphadenectomy.
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